Expert Interview
Discussing the standard of care and potential of AstraZeneca’s FASENRA (benralizumab) which is now FDA approved for patients with severe asthma aged 6 to 11
Ticker(s): AZNDr. Gondi is Board Certified in Allergy, Clinical Immunology, and Pediatrics. He Sees over 300 patients with Urticaria. He has Keen interest in treating allergic rhinitis, asthma, sinus disease, and insect sting allergies.He is a Diplomate of the American Board of Allergy and Immunology, Diplomate of the American Board of Pediatrics, and Fellow of the American Academy of Allergy, Asthma, and Immunology.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
